Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) reached a new 52-week high on Thursday . The company traded as high as $4.67 and last traded at $4.67, with a volume of 0 shares changing hands. The stock had previously closed at $0.09.
Matinas BioPharma Price Performance
The firm has a market capitalization of $1.17 billion, a PE ratio of -38.88 and a beta of 1.70.
Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.02).
Institutional Inflows and Outflows
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
Further Reading
- Five stocks we like better than Matinas BioPharma
- Investing in Construction Stocks
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- What Are Dividends? Buy the Best Dividend Stocks
- Why Dell Can Continue Winning in AI and Beyond
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.